Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 38
1967 85
1968 95
1969 94
1970 109
1971 128
1972 150
1973 156
1974 188
1975 209
1976 205
1977 227
1978 214
1979 240
1980 216
1981 218
1982 225
1983 230
1984 249
1985 220
1986 254
1987 262
1988 304
1989 390
1990 393
1991 455
1992 495
1993 502
1994 589
1995 647
1996 648
1997 738
1998 663
1999 701
2000 711
2001 686
2002 724
2003 675
2004 705
2005 716
2006 876
2007 757
2008 802
2009 773
2010 800
2011 1098
2012 1108
2013 991
2014 1055
2015 925
2016 727
2017 736
2018 806
2019 1040
2020 300
Text availability
Article attribute
Article type
Publication date

Search Results

24,828 results
Results by year
Filters applied: . Clear all
Page 1
Retraction
[No authors listed] Int J Cancer 2019. PMID 31219630
Int. J. Cancer, 125: 2077-2085. doi: 10.1002/ijc.24572 The above article, published online on 15 May 2009 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor in Chief, Professor Christoph Plass, the Union for International Cancer Control and John Wiley & Sons, Ltd. ...
Int. J. Cancer, 125: 2077-2085. doi: 10.1002/ijc.24572 The above article, published online on 15 May 2009 in Wiley Onli
Retraction
[No authors listed] Int J Cancer 2019. PMID 31283016
Retraction
[No authors listed] Int J Cancer 2019. PMID 31283014
Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int. J. Cancer, 115: 630-640. https://doi.org/10.1002/ijc.20917.
[No authors listed] Int J Cancer 2019. PMID 31099426
Peter Lichter, the Union for International Cancer Control and John Wiley & Sons, Ltd. The retraction has been agreed due to reuse of several figure panels in the paper. ...Reference International Journal of Cancer Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro Volume 115, Issue 4, 1 July 2005, Pages: 630-640, Claudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, Danilo Millimaggi, Paola Muzi, Carlo Vicentini and Mauro Bologna Version of Record online : 7 FEB 2005, DOI: 10.1002/ijc.20917....
Peter Lichter, the Union for International Cancer Control and John Wiley & Sons, Ltd. The retraction has been agreed due to reuse …
More options for adjuvant treatment of HER2-positive breast cancer: How to choose wisely?
Trapani D, et al. Int J Cancer 2019 - Review. PMID 31107981
Human epidermal growth factor receptor 2-positivity (HER2) has a prognostic and predictive role in breast cancer. Trastuzumab, an anti-HER2 therapy, has a crucial role in a curative setting in Stage I, II and III breast cancer. ...Newer dosing strategies and combination approaches give us a plethora of options to treat a patient with early-stage and locally advanced breast cancer. ...
Human epidermal growth factor receptor 2-positivity (HER2) has a prognostic and predictive role in breast cancer. Trastuzumab, an ant …
In search of definitions: Cancer-associated fibroblasts and their markers.
Nurmik M, et al. Int J Cancer 2020 - Review. PMID 30734283 Free PMC article.
Inside this microenvironment, cancer-associated fibroblasts (CAFs), a type of perpetually activated fibroblasts, have been implicated to have a strong tumor-modulating effect and play a key role in areas such as drug resistance. ...
Inside this microenvironment, cancer-associated fibroblasts (CAFs), a type of perpetually activated fibroblasts, have been implicated …
The spectrum of mutations predisposing to familial breast cancer in Poland.
Cybulski C, et al. Int J Cancer 2019. PMID 31173646
We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes. ...A simple test for these 20 mutations will facilitate genetic testing for breast cancer susceptibility in Poland. It may also facilitate genetic testing for breast cancer susceptibility in other Slavic populations and women of Slavic descent worldwide....
We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genet …
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Grünewald S, et al. Int J Cancer 2019. PMID 30807645 Free PMC article.
Aberrant activation in fibroblast growth factor signaling has been implicated in the development of various cancers, including squamous cell lung cancer, squamous cell head and neck carcinoma, colorectal and bladder cancer. ...In line with this, rogaratinib reduced proliferation in FGFR-addicted cancer cell lines of various cancer types including lung, breast, colon and bladder cancer. ...
Aberrant activation in fibroblast growth factor signaling has been implicated in the development of various cancers, including squamous cell …
Prospective serum metabolomic profiling of lethal prostate cancer.
Huang J, et al. Int J Cancer 2019 - Clinical Trial. PMID 30779128 Free PMC article.
Impaired metabolism may play an important role in the pathogenesis of lethal prostate cancer, yet there is a paucity of evidence regarding the association. We conducted a large prospective serum metabolomic analysis of lethal prostate cancer in 523 cases and 523 matched controls nested within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. ...
Impaired metabolism may play an important role in the pathogenesis of lethal prostate cancer, yet there is a paucity of evidence rega …
New perspectives on screening and early detection of endometrial cancer.
Costas L, et al. Int J Cancer 2019 - Review. PMID 31199503
Recent research findings offer a promising perspective in the detection of endometrial cancer, but certain questions need to be addressed in order to accelerate the implementation of novel technologies in a routine screening or clinical setting. We discuss here new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods with a special focus on public health classic screening criteria, highlighting current gaps in knowledge....
Recent research findings offer a promising perspective in the detection of endometrial cancer, but certain questions need to be addre …
24,828 results
Jump to page
Feedback